245 related articles for article (PubMed ID: 14738561)
21. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
Yang H; Westland CE; Delaney WE; Heathcote EJ; Ho V; Fry J; Brosgart C; Gibbs CS; Miller MD; Xiong S
Hepatology; 2002 Aug; 36(2):464-73. PubMed ID: 12143057
[TBL] [Abstract][Full Text] [Related]
22. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.
Carrouée-Durantel S; Durantel D; Werle-Lapostolle B; Pichoud C; Naesens L; Neyts J; Trépo C; Zoulim F
Antivir Ther; 2008; 13(3):381-8. PubMed ID: 18572751
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
Gallego A; Sheldon J; García-Samaniego J; Margall N; Romero M; Hornillos P; Soriano V; Enrĺquez J
J Viral Hepat; 2008 May; 15(5):392-8. PubMed ID: 18221300
[TBL] [Abstract][Full Text] [Related]
24. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
[TBL] [Abstract][Full Text] [Related]
25. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
[TBL] [Abstract][Full Text] [Related]
26. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
[TBL] [Abstract][Full Text] [Related]
27. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
Zhao H; Zhang YX; Chen XY; Wang L; Tang XP; Si CW
Zhonghua Nei Ke Za Zhi; 2007 Apr; 46(4):294-7. PubMed ID: 17637268
[TBL] [Abstract][Full Text] [Related]
28. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
29. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
[TBL] [Abstract][Full Text] [Related]
30. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Peters MG; Hann Hw Hw; Martin P; Heathcote EJ; Buggisch P; Rubin R; Bourliere M; Kowdley K; Trepo C; Gray Df Df; Sullivan M; Kleber K; Ebrahimi R; Xiong S; Brosgart CL
Gastroenterology; 2004 Jan; 126(1):91-101. PubMed ID: 14699491
[TBL] [Abstract][Full Text] [Related]
31. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
Lampertico P; Viganò M; Manenti E; Iavarone M; Lunghi G; Colombo M
Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
[TBL] [Abstract][Full Text] [Related]
32. Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy.
van Bömmel F; Trojan J; Deterding K; Wedemeyer H; Wasmuth HE; Hüppe D; Möller B; Bock FJ; Feucht HH; Berg T
Antivir Ther; 2012; 17(6):1049-58. PubMed ID: 22892524
[TBL] [Abstract][Full Text] [Related]
33. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
34. [A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B].
Lin XH; Si CW; Yu YY; Li J; Chen XY; Ren XM; Liu P; Zhang SL; Kang XP
Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):898-901. PubMed ID: 17196132
[TBL] [Abstract][Full Text] [Related]
35. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus.
Julander JG; Sidwell RW; Morrey JD
Antiviral Res; 2002 Jul; 55(1):27-40. PubMed ID: 12076749
[TBL] [Abstract][Full Text] [Related]
36. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.
Gilson RJ; Chopra KB; Newell AM; Murray-Lyon IM; Nelson MR; Rice SJ; Tedder RS; Toole J; Jaffe HS; Weller IV
J Viral Hepat; 1999 Sep; 6(5):387-95. PubMed ID: 10607255
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of adefovir dipivoxil was not related to genotypes B and C of hepatitis B virus: a randomized, double-blind, multicenter clinical study].
Zhao H; Li J; Zhang YX; Chen XY; Wang L; Tang XP; Lei CL; Si CW
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):282-4. PubMed ID: 17971947
[TBL] [Abstract][Full Text] [Related]
38. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
N Engl J Med; 2003 Feb; 348(9):800-7. PubMed ID: 12606734
[TBL] [Abstract][Full Text] [Related]
39. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Benhamou Y; Bochet M; Thibault V; Calvez V; Fievet MH; Vig P; Gibbs CS; Brosgart C; Fry J; Namini H; Katlama C; Poynard T
Lancet; 2001 Sep; 358(9283):718-23. PubMed ID: 11551579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
